Evidence map›Paper›PMID 36470669›Full record

ArticleAging2022

Upregulated UBE4B expression correlates with poor prognosis and tumor immune infiltration in hepatocellular carcinoma.

Xuyang Shao, Jun Zhu, Yanlong Shi, Hanlu Fang, Jingsi Chen, Yixiao Zhang, Jingyan Wang, Haokun Jian, Sheng Lan, Fei Jiang and 3 more

Open access · hybridAbstract read
In one paragraph

Article in Aging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 11 institutions in 1 country.

Xuyang ShaoGraduate School of Bengbu Medical College, Bengbu 233000, Anhui Province, China.
Jun ZhuDepartment of Oncology, Fuyang Hospital of Anhui Medical University, Fuyang 236000, Anhui Province, China.
Yanlong ShiHepatopancreatobiliary Center, The Second Affiliated Hospital of Nanjing Medical University, Nanjing 210003, Jiangsu Province, China.
Hanlu FangInstitute of Medical and Health Science of HeBMU, Hebei Medical University, Shijiazhuang 050017, Hebei Province, China.
Jingsi ChenDepartment of Intensive Care Unit, Fuyang Women and Children's Hospital, Fuyang 236000, Anhui Province, China.
Yixiao ZhangThe First Clinical College of Zhejiang Chinese Medical University, Hangzhou 310053, Zhejiang Province, China.
Jingyan WangDepartment of Anesthesia, Shaoxing People's Hospital, Shaoxing 312000, Zhejiang Province, China.
Haokun JianSchool of Basic Medical Sciences, Xinxiang Medical University, Xinxiang 453003, Henan Province, China.
Sheng LanThe Second Clinical College of Guangzhou Medical University, Guangzhou 510030, Guangdong Province, China.
Fei JiangDepartment of General Surgery, Fuyang Hospital of Anhui Medical University, Fuyang 236000, Anhui Province, China.
Fei ZhongDepartment of Oncology, Fuyang Hospital of Anhui Medical University, Fuyang 236000, Anhui Province, China.
Yewei ZhangHepatopancreatobiliary Center, The Second Affiliated Hospital of Nanjing Medical University, Nanjing 210003, Jiangsu Province, China.
Chenxi CaoGraduate School of Bengbu Medical College, Bengbu 233000, Anhui Province, China.
Anhui Medical University · CNZhejiang Chinese Medical University · CNBengbu Medical College · CNFuyang Maternity and Child Health Care Hospital · CNFuyang Second People's Hospital · CNHebei Medical University · CNJiaxing University · CNSecond Affiliated Hospital of Guangzhou Medical University · CNSecond Affiliated Hospital of Nanjing Medical University · CNShaoxing People's Hospital · CNXinxiang Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatocellular carcinoma (HCC) is a major human health concern. Increasing evidence has demonstrated that ubiquitin ligase E4B (UBE4B) may be involved in the occurrence and development of various human cancers and may affect prognosis. However, the specific role and mechanism of UBE4B in HCC is unclear.

methodsA pan-cancer analysis of UBE4B expression, clinicopathological features, and prognosis was performed using bioinformatics techniques. Subsequently, the expression, prognosis, and correlation of UBE4B and its upstream miRNAs and lncRNAs were analyzed. We investigated the relationship between UBE4B expression and immune cell infiltration, immunomodulatory factors, and chemokines in HCC. The expression levels of UBE4B and its upstream lncRNAs (FGD5-AS1, LINC00858, and SNHG16) and miRNAs (hsa-miR-22-3p) were evaluated in HCC cell lines using qRT-PCR.

resultsUBE4B expression increased in HCC and was correlated with a poor survival rate in patients with HCC. A ceRNA network was established to identify the UBE4B-hsa-miR-22-3p-FGD5-AS1/LINC00858/SNHG16 regulatory axis in HCC. UBE4B expression was significantly associated with immune cell infiltration, immunomodulators, chemokines, and their receptors in HCC. The mRNA expression of FGD5-AS1, LINC00858, SNHG16, and UBE4B was higher in the HCC cell lines (7721 and HepG2) than in the normal hepatocyte line (LO2), and the expression of hsa-miR-22-3p mRNA showed a decreasing trend.

conclusionsOur findings showed that upregulation of UBE4B was associated with poor prognosis and tumor immune infiltration in HCC. These findings will aid in understanding the relevant functions of UBE4B and provide new strategies for drug development and exploration of prognosis-related biomarkers.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsMicroRNAsRNA, Long NoncodingCell Line, TumorGene Expression Regulation, NeoplasticHumansPrognosisUbiquitin-Protein LigasesMicroRNAsRNA, Long NoncodingUBE4B protein, humanUbiquitin-Protein Ligasescompeting endogenous RNAhepatocellular carcinomapan-cancer analysisprognosis-related biomarkerubiquitin ligase

Identifiers

PMID36470669
PMCPMC9792214
OpenAlexW4310784309

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.